China’s NDRC summons pharmaceutical companies for inquiries over alleged abuse of patents
A cluster of international and domestic pharmaceutical companies in China were recently summoned by the antitrust regulator, the National Development and Reform Commission, for inquiries about alleged abuse of patents, MLex...To view the full article, register now.
Already a subscriber? Click here to view full article